Will Tilray (TLRY) Expanding Into Panama Reveal New Strengths in Its Global Growth Strategy?

• Tilray Medical has expanded its medical cannabis operations into Panama through a joint venture with Top Tech Global Inc., receiving a license from the National Directorate of Pharmacy and Drugs to cultivate, manufacture, import, export, distribute, and sell medical cannabis in the country.
• This move underscores Tilray's ongoing commitment to broadening patient access by leveraging local partnerships and signals a further step in its global growth ambitions.
• We'll examine how Tilray's entry into Panama through its local licensing partnership could reshape its international expansion narrative.

We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Tilray Brands Investment Narrative Recap

To own Tilray Brands stock, you need to believe in the company’s ability to turn international expansion, like its recent entry into Panama, into meaningful revenue growth, while overcoming persistent losses and competitive headwinds. The new Panama venture reflects progress on global ambitions, but its near-term effect on Tilray’s most pressing catalysts, namely broader international cannabis adoption, and exposure to ongoing risks like price compression and profitability challenges, is not yet material.

Among the recent announcements, Tilray's Q1 2026 earnings stand out: the company reported a smaller net loss of US$322,000 on sales of US$209.5 million, improving on the prior year. This hints at incremental progress toward margin improvement, but the ongoing struggle for operating profitability remains closely tied to both new market execution and relief from price pressures.

Yet, despite encouraging global steps, investors should be aware of the impact that persistent losses and negative cash flow can have over time, especially if...

Read the full narrative on Tilray Brands (it's free!)

Tilray Brands' outlook suggests revenues of $940.4 million and earnings of $193.4 million by 2028. This is based on an assumed 4.6% annual revenue growth rate and a dramatic earnings increase of about $2.4 billion from current earnings of -$2.2 billion.

Uncover how Tilray Brands' forecasts yield a $1.11 fair value, a 29% downside to its current price.

Exploring Other Perspectives

Twenty individual fair value estimates from the Simply Wall St Community span US$0.65 to US$45 per share. As international expansion continues, the wide disparity in views highlights uncertainty surrounding Tilray’s path to sustainable profitability, so see how your assessment compares.

Explore 20 other fair value estimates on Tilray Brands - why the stock might be worth less than half the current price!

Build Your Own Tilray Brands Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Tilray Brands research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Tilray Brands research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tilray Brands' overall financial health at a glance.

Want Some Alternatives?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find companies with promising cash flow potential yet trading below their fair value.
• These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 36 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com